Last updated: 9 November 2023 at 7:09pm EST

Partners, L.P.Bradsher Neal... Net Worth




The estimated Net Worth of Partners, L.P.Bradsher Neal... is at least $66.9 Million dollars as of 7 November 2023. Partners Neal owns over 289,140 units of Oncocyte stock worth over $31,210,853 and over the last 11 years Partners sold OCX stock worth over $35,650,815.

Partners Neal OCX stock SEC Form 4 insiders trading

Partners has made over 15 trades of the Oncocyte stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners bought 289,140 units of OCX stock worth $9,663,059 on 7 November 2023.

The largest trade Partners's ever made was buying 6,003,752 units of Oncocyte stock on 13 April 2022 worth over $7,984,990. On average, Partners trades about 423,408 units every 173 days since 2013. As of 7 November 2023 Partners still owns at least 10,068,017 units of Oncocyte stock.

You can see the complete history of Partners Neal stock trades at the bottom of the page.



Insiders trading at Oncocyte

Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.



What does Oncocyte do?

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.



What does Oncocyte's logo look like?

Oncocyte Corporation logo

Complete history of Partners Neal stock trades at Staar Surgical Co and Oncocyte

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
7 Nov 2023 Partners, L.P.Bradsher Neal...
Buy 289,140 $33.42 $9,663,059
7 Nov 2023
10,068,017
24 Jun 2021 Partners, L.P.Bradsher Neal...
Sale 228,443 $156.06 $35,650,815
24 Jun 2021
8,664,239
17 May 2016 Partners, L.P.Bradsher Neal...
Buy 9,313 $5.23 $48,707
17 May 2016
10,763,193
28 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 65,983 $6.48 $427,570
28 Jan 2016
9,650,235
28 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 65,983 $6.48 $427,570
28 Jan 2016
9,650,235
25 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 239,013 $6.63 $1,584,656
25 Jan 2016
9,584,252
25 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 239,013 $6.63 $1,584,656
25 Jan 2016
9,584,252
13 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 135,725 $6.73 $913,429
13 Jan 2016
9,272,381
13 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 135,725 $6.73 $913,429
13 Jan 2016
9,272,381
5 Jan 2016 Partners, L.P.Bradsher Neal...
Buy 267,047 $6.95 $1,855,977
5 Jan 2016
9,050,070
30 Dec 2015 Partners, L.P.Bradsher Neal...
Buy 165,461 $7.11 $1,176,428
30 Dec 2015
8,783,023
17 Nov 2014 Partners, L.P.Bradsher Neal...
Buy 189,646 $8.64 $1,638,541
17 Nov 2014
7,417,582
10 Nov 2014 Partners, L.P.Bradsher Neal...
Buy 500 $8.79 $4,395
10 Nov 2014
7,227,936
13 Apr 2022 Partners, L.P.Bradsher Neal...
Buy 6,003,752 $1.33 $7,984,990
13 Apr 2022
23,353,697


Oncocyte executives and stock owners

Oncocyte executives and other stock owners filed with the SEC include: